The tumor growth promoting benefits of Atg5 or Atg7 loss of expression has also been demonstrated in several experimental models, such as in the BRAFV600E driven lung carcinomas or in the KRASG12D or driven pancreatic cancer [41, 42]. This evidence concerns the gene ATG7 and neoplasm.